维莫非尼用于治疗出现双侧眼眶受累的BRAF V600突变型 Erdheim-Chester病。
Vemurafenib for BRAF V600-mutant Erdheim-Chester disease presenting with bilateral orbital involvement.
作者信息
Wang Xiaomeng, Cao Jie, Du Weijiao, Ma Wenchao, Meng Bin, Cao Shui
机构信息
Tianjin Medical University Cancer Institute and Hospital Tianjin China.
Cancer Immunotherapy Department Tianjin Cancer Hospital Airport Hospital Tianjin China.
出版信息
Clin Case Rep. 2023 Aug 21;11(8):e7780. doi: 10.1002/ccr3.7780. eCollection 2023 Aug.
Abstract
ECD is considered to have rapid progression and poor prognosis. Studies have shown that vemurafenib is effective for ECD patients with orbital involvement, but not for ECD with multiple organs. The refinement of treatment approaches and the increased awareness of ECD have led to a dramatic improvement in prognosis.
摘要
ECD被认为进展迅速且预后不良。研究表明，维莫非尼对有眼眶受累的ECD患者有效，但对多器官受累的ECD无效。治疗方法的改进以及对ECD认识的提高已使预后得到显著改善。
Zotero 插件